NOMAD-FOODS
9.5.2022 11:43:08 CEST | Business Wire | Press release
Nomad Foods, Europe’s leading frozen food company, which owns brands including Birds Eye, Findus and iglo, is calling on the food industry and regulators across Europe to consider a more comprehensive, end-to-end approach to Life Cycle Assessment (LCA) studies, which includes food loss and waste impacts, to improve transparency for consumers and drive critical action to reduce carbon emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005425/en/
Food production is a major contributor to climate change and making better environmental choices about what we eat and how we reduce food waste is one way for businesses and consumers to lower their carbon impact. To support this action, it’s vital that food companies fully understand their products’ total emissions footprint and provide clear, accurate and complete information.
With carbon labels and previous LCA studies on food often limited in scope, Nomad Foods has recently enlisted the help of international experts in impact assessments, PRé Sustainability, to conduct a unique end-to-end LCA study for 22 of Nomad Foods’ most popular products1 .
Crucially, the study went beyond the scope of existing LCAs to include all stages of the product life cycle, incorporating new data on retailer and consumer food waste (an important element of Scope 3 emissions for food manufacturers) and primary data for all processing steps, improving the accuracy of the assessment – with the results peer reviewed by leading experts.
The study showed that retail and consumer food loss and waste – data which is not generally included in previous LCA assessments of food – plays an important part of the product life cycle and has a significant effect on a product’s overall environmental impact. In fact, retail and consumer food waste equates to an estimated 160m tonnes and 17.25m tonnes of CO2 in the EU and UK respectively2 .
This new assessment means that, for the first time ever, clear conclusions can be drawn about the carbon footprint of frozen foods products and meaningful comparisons made to their non-frozen alternatives, while accounting for all relevant and material impacts. Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods.
Stéfan Descheemaeker, Chief Executive Officer, Nomad Foods, said: “Consumer demand for nutritious, high-quality, sustainable food is growing and we believe it’s vital that we find ways to provide consumers with information that helps them make informed choices and provides confidence that sustainability claims are robust and evidence-based. To support this, we encourage the food industry, retailers and regulators to adopt a wider scope for LCAs as standard, taking the whole product life cycle into account. Based on the ground-breaking work that our teams have undertaken with life cycle experts PRé Sustainability, we can see there are significant benefits to frozen food in terms of longer-term food preservation and reduced food waste.”
Ellen Meijer, Consultant, PRé Sustainability, said: “This is one of the most elaborate frozen food LCA studies ever done, covering not only a wide range of frozen food products and their alternatives, but also approaching them all in a consistent methodological manner. Combined with the large amount of primary production data included and the attention to detail at each stage, this study is one of a kind. Based on this study, we are now in the unique position to draw conclusions about the carbon footprint of frozen food products compared to their non-frozen alternatives and generalize these conclusions across the frozen food category."
About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe’s leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye
, Findus
, iglo
, Ledo
and Frikom
, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com
.
About PRé Sustainability
For thirty years PRé Sustainability has been at the forefront of life cycle thinking and has built on its knowledge and experience in sustainability metrics and impact assessments to provide state of the art methods, consulting services and software tools. Internationally, leading organizations work with PRé to integrate sustainability into their product development procedures in order to create business growth and business value. PRé has an office in the Netherlands and a global partner network to support large international or multi-client projects. www.pre-sustainability.com
.
Notes to Editors:
1 The comprehensive LCA study covered 10 keys stages. Stages 6 – 10 are the extended scope of the assessment not generally included in other studies :
- Ingredients : Production, including transport to factory.
- Processing : All activities that happen at the factory including energy, on-site waste and the treatment of it, and activities related to packaging the product. Also includes any pre-blanching or pre-freezing before it reaches the factory. The study included primary data for all material processes improving the accuracy of the assessment.
- Packaging : Packaging materials, including their transport to the factory.
- Distribution : Transport from the factory, storage at the distribution centre, transport to the retail hub and storage at the retail hub.
- Retail storage : Electricity and coolant use in the retail cold room and on the retail floor.
- Retail waste : Waste treatment of transport packaging, product losses and waste treatment of product losses, including processing, packaging and distribution of the product losses.
- Consumer transport : From the retailer to the consumer.
- Consumer storage : Electricity use for storage at the consumer.
- Consumer preparation : Energy use at the consumer to cook the food product, as well as any capital goods.
- Consumer waste : Waste treatment of primary packaging and product losses. This includes all upstream processes required to compensate for the product losses at the consumer.
2 6.9m tonnes of the UK’s annual total of 9.5m tonnes of food waste is down to the retailer and consumer, equivalent to 17.25m tonnes of CO2 (WRAP). In the EU the retail and consumer proportion of the 88m tonnes of food waste generated, equates to 160m tonnes of CO2. Calculation based on 1 kg of food waste creates 2.5 kg of CO22013; Food Wastage Footprint Impact on Natural Resources; United Nation’s Food & Agriculture Organization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
